14 completed, 6 terminated, 2 withdrawn, 1 suspended. 14 Phase 2, 6 Phase 3, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 11, Withdrawn 2, Suspended 1 |
| Phase 3 | 6 | Terminated 6 |
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow gevokizumab: new trials by email Literature Review of gevokizumab trials Research Report on gevokizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy Gevokizumab, Signatera test - Colon Cancer | Phase 2 | Withdrawn | NSABP Foundation Inc | 2022-06-24 | 2022-11-04 | |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Gevokizumab, Bevacizumab, Modified FOLFOX6 - Colorectal Cancer, Gastroesophageal Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 167 | 2019-05-22 | 2026-04-01 |
| An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum gevokizumab, Placebo, gevokizumab open-label - Pyoderma Gangrenosum | Phase 3 | Terminated | XOMA (US) LLC | 9 | 2014-12-01 | 2016-04-27 |
| Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Placebo, Gevokizumab - Behcet's Disease Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 4 | 2014-11-01 | 2015-12-29 |
| An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum gevokizumab, Placebo, gevokizumab open-label - Pyoderma Gangrenosum | Phase 3 | Terminated | XOMA (US) LLC | 16 | 2014-11-01 | 2016-04-27 |
| A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum gevokizumab - Pyoderma Gangrenosum | Phase 3 | Terminated | XOMA (US) LLC | 15 | 2014-11-01 | 2016-04-27 |
| Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Gevokizumab - Chronic Uveitis | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 71 | 2014-08-01 | 2020-01-03 |
| The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease gevokizumab - Autoimmune Inner Ear Disease | Phase 2 | Completed | XOMA (US) LLC | 10 | 2013-08-01 | 2016-02-03 |
| Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum gevokizumab - Pyoderma Gangrenosum | Phase 2 | Completed | XOMA (US) LLC | 8 | 2013-05-01 | 2016-02-03 |
| Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand Placebo, gevokizumab - Osteoarthritis | Phase 2 | Completed | XOMA (US) LLC | 91 | 2013-05-01 | 2014-03-04 |
| Gevokizumab for Active Scleritis Gevokizumab - Scleritis | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 8 | 2013-03-01 | 2018-07-06 |
| Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand gevokizumab - Osteoarthritis | Not applicable | Completed | XOMA (US) LLC | 312 | 2013-03-01 | 2015-02-19 |
| Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) Gevokizumab, Placebo - Behcet's Uveitis | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 84 | 2012-11-01 | 2020-01-03 |
| Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand Placebo, gevokizumab - Osteoarthritis | Phase 2 | Completed | XOMA (US) LLC | 87 | 2012-07-01 | 2014-03-04 |
| Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris Placebo, gevokizumab - Acne Vulgaris | Phase 2 | Completed | XOMA (US) LLC | 127 | 2011-12-01 | 2014-03-04 |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 | |
| Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus XOMA 052, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | XOMA (US) LLC | 76 | 2010-05-01 | 2012-05-16 |
| Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes Xoma 052, Placebo - Type 1 Diabetes | Phase 2 | Completed | XOMA (US) LLC | 22 | 2010-02-01 | 2014-03-04 |
| Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy XOMA 052, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | XOMA (US) LLC | 421 | 2010-01-01 | 2011-10-04 |
| Effects of XOMA 052 on Insulin Production in Type 1 Diabetes XOMA 052, Placebo - Diabetes Mellitus Type 1 | Phase 2 | Completed | University of Zurich | 22 | 2009-09-01 | 2014-02-11 |
Showing 20 of 23. Sign in to see all of them.
Diabetes Mellitus (5) · Diabetes Mellitus, Type 2 (4) · Pyoderma Gangrenosum (4) · Osteoarthritis (3) · Behcet Syndrome (2) · Diabetes Mellitus, Type 1 (2) · Uveitis (2) · Acne Vulgaris (1) · Arthritis (1) · Arthritis, Rheumatoid (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Cryopyrin-Associated Periodic Syndromes (1) · Hearing Loss, Sudden (1)
XOMA (US) LLC (16) · Institut de Recherches Internationales Servier (2) · NSABP Foundation Inc (1) · National Eye Institute (NEI) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Novartis Pharmaceuticals (1) · University of Zurich (1)
United States (17) · Australia (4) · Canada (3) · South Korea (3) · Switzerland (3) · United Kingdom (3) · Germany (2) · Italy (2) · Spain (2) · Taiwan (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · France (1)
Marc Donath, MD (2) · Pedro Urquilla, MD (2) · Alan Solinger, M.D. (1) · Hatice N Sen, M.D. (1) · Marc Donath, Prof. (1) · Norman Wolmark, MD (1)
PMID 29370572, PMID 21949230, PMID 22699287, PMID 27663070
2018 (1), R33DC011827 (1)